ESG Data

アンカーリンク用

Regarding the data for FY2021 marked with ★, we have received independent assurance in our SUSTAINABILITY DATA 2022 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Board structure	Directors (Total)	Non-consolidated	Persons	7	8	8	8	8
	Independent outside directors	Non-consolidated	Persons	2	3	3	3	3
	Female directors	Non-consolidated	Persons	0	0	0	1	1
Board of Auditors structure	Auditors (Total)	Non-consolidated	Persons	4	4	4	4	4
	Independent outside auditors	Non-consolidated	Persons	2	2	2	2	2
	Female auditors	Non-consolidated	Persons	1	1	1	1	1
Director Remuneration	Total	Non-consolidated	Million yen	336	360	368	384	428
Director Remuneration	President, Representative Director, and Chief Executive Officer	Non-consolidated	Million yen	-	114	116	126	125
Auditor Remuneration	Total	Non-consolidated	Million yen	76	77	78	83	85
Number of Board of Directors meetings		Non-consolidated	Times	13	13	13	13	15
Number of Board of Auditors meetings		Non-consolidated	Times	13	14	14	19	16
Board attendance rate（directors）		Non-consolidated	%	100	100	100	98.6	100
Board attendance rate（auditors）		Non-consolidated	%	-	100	92.3^*1	100	100

The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.

Compliance
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Compliance training attendance rate		Non-consolidated	%	-	100	100	100	100
Number of reports	Discrimination and harassment related	Non-consolidated	Incidents	-	-	22	15	29
	Personnel and labor management related	Non-consolidated	Incidents	-	-	2	1	2
	Others	Non-consolidated	Incidents	-	-	44	6	29
	Total	Non-consolidated	Incidents	-	44	68	22	60
Number of compliance violations（Disciplinary action cases）	Discrimination and harassment related	Non-consolidated	Incidents	-	-	3	1	0
	Personnel and labor management related	Non-consolidated	Incidents	-	-	0	0	1
	Bribery cases	Non-consolidated	Incidents	0	0	0	1	0
	Others	Non-consolidated	Incidents	-	-	6	0	10
	Total	Non-consolidated	Incidents	-	5	9	2	11
Costs for legal violations		Non-consolidated	Million yen	-	-	-	0	0
Number of facilitation payments		Non-consolidated	Incidents	0	0	0	0	0

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

Research Development
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
R&D expenses	Non-consolidated	Million yen	68,821	70,008	66,497	62,384	75,879
Ratio of R&D expenses to net sales	Non-consolidated	％	26.3	24.3	22.7	20.2	21.0

Provision of Growth Opportunities
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Average hours of training and development per employee		Consolidated	Hours	-	-	-	-	50.8
Average hours of training and development per employee		Non-consolidated	Hours	-	35.5	30.7	34.1	53.8
Classification by training category	General capability development	Consolidated	Hours	-	-	39,189	69,080	63,161
	General capability development	Consolidated	Participants	-	-	16,194	16,867	23,013
	Professional capability development	Consolidated	Hours	-	-	57,226	43,214	84,870
	Professional capability development	Consolidated	Participants	-	-	11,012	13,072	23,414
	Compliance training	Consolidated	Hours	-	-	6,885	3,816	36,179
	Compliance training	Consolidated	Participants	-	-	13,999	33,503	38,276
	General capability development	Non-consolidated	Hours	-	-	-	-	60,479
	General capability development	Non-consolidated	Participants	-	-	-	-	22,568
	Professional capability development	Non-consolidated	Hours	-	-	-	-	82,325
	Professional capability development	Non-consolidated	Participants	-	-	-	-	21,720
	Compliance training	Non-consolidated	Hours	-	-	-	-	34,811
	Compliance training	Non-consolidated	Participants	-	-	-	-	37,412

For more information on the training, see "Human Resources Development."

Employees information
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Employees (total)		Non-consolidated	Persons	3,199	3,284	3,287	3,319	3,354
Employees (male)		Non-consolidated	Persons	2,649	2,682	2,676	2,688	2,696
Employees (female)		Non-consolidated	Persons	570	602	611	631	658
Employees (female)		Non-consolidated	％	17.8	18.3	18.6	19.0	19.6
Contract workers ratio		Non-consolidated	％	0.3	0.1	0.1	0.1	0.1
Temporary staff ratio		Non-consolidated	％	8.8	8.9	8.0	8.8	9.3
Average age (total)		Non-consolidated	Years old	41.4	41.8	41.9	42.7	43.0
Average age (male)		Non-consolidated	Years old	42.1	42.6	42.7	43.7	44.1
Average age (female)		Non-consolidated	Years old	37.9	38	37.9	38.5	38.7
Employee age group ratio	<30 years old	Non-consolidated	％	-	-	-	13.3	14.0
	30-50 years old	Non-consolidated	％	-	-	-	61.7	60.0
	>50　years old	Non-consolidated	％	-	-	-	25.0	26.0
Average consecutive years of employment (total)		Non-consolidated	Years	15.3	15.5	16	16.3	16.5
Average consecutive years of employment (male)		Non-consolidated	Years	16	16.3	16.8	17.2	17.5
Average consecutive years of employment (female)		Non-consolidated	Years	11.8	12	12.4	12.5	12.4
Average annual salary of employees		Non-consolidated	JPY 10,000	906	917	928	937	947
Collective bargaining rights holding rate		Non-consolidated	％	-	-	97.3	95.7	96.0
Labor union participation rate		Non-consolidated	％	66.8	65.1	60.8	62.2	58.6

Diversity and Inclusion
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Employment of persons with disabilities	Non-consolidated	％	2.24	2.28	2.2	2.17	2.38
Female manager rate	Non-consolidated	％	3.9	4.0	4.6	4.6	5.2

Recruitment^＊
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Total number of newemployee hires	Total^＊	Non-consolidated	Persons	166	161	88	105	131
	New graduates	Non-consolidated	Persons	98	87	71	73	82
	Mid-careers^＊	Non-consolidated	Persons	68	74	17	32	49
Ratio of new graduates (male)^＊		Non-consolidated	％	66	51	66	60	60
Ratio of new graduates (female)^＊		Non-consolidated	％	34	49	34	40	40

We have corrected some errors in the recruitment section for FY2021.
【Total】 Error：132　⇒　Correct：131　　【Mid-careers】Error：50　⇒　Correct：49
【Ratio of new graduates (male／female)】Error：62／38　⇒　Correct：60／40

Employee Engagement
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Actively engaged employees ^*2(total)	Non-consolidated	％	-	66	-	79	-
Actively engaged employees (male)	Non-consolidated	％	-	68	-	80	-
Actively engaged employees (female)	Non-consolidated	％	-	57	-	74	-

We review our employee engagement indicators and calculation methods each time.

Turnover and retention rate
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Retention rate after 3 years (total)	Non-consolidated	％	97.8	97.8	93.9	96.6	91.5
Retention rate after 3 years (male)	Non-consolidated	％	98.4	96.1	95.4	97.7	93.6
Retention rate after 3 years (female)	Non-consolidated	％	96.9	100.0	90.9	95.3	87.5
Full-time employee turnover rate (voluntary resignation)	Non-consolidated	％	1.3	1.5	1.6	1.2	1.7
Full-time employee turnover rate (Mandatory retirement, etc.)	Non-consolidated	％	0.7	0.6	0.2	1.1	1.7
Full-time employee turnover rate (total)	Non-consolidated	％	2.0	2.1	1.8	2.3	3.4

Enhancing cultivation of employee-friendly workplaces
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Overtime hours	Non-consolidated	hours / month	15.4	14.9	13.6	15.3	16.3
Percentage of paid vacation taken	Non-consolidated	%	56.8	56	65	57.5	62.5

Health and safety
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020
Industrial accident	Number of lost-time injuries	Non-consolidated (Employees)	Incidents	1	1	0	3
	Number of lost-time injuries	Non-consolidated (Temporary employees)^*4	Incidents	-	-	1	0
	Lost-time injury frequency rate^*3	Non-consolidated (Employees)	-	0.16	0.15	0	0.47
	Lost-time injury frequency rate^*3	Non-consolidated (Temporary employees)^*4	-	-	-	2.09	0
	Number of fatalities due to occupational accidents	Non-consolidated (Employees)	Persons	0	0	0	0
	Number of fatalities due to occupational accidents	Non-consolidated (Temporary employees)^*4	Persons	0	0	0	0

Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000
The data on the number of lost-time injuries and the lost-time injury frequency rate for temporary employees are subject to disclosure from FY2019.

Supporting disease prevention, early detection and early treatment
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Comprehensive medical examination rate		Non-consolidated	％	99.1	99.4	99.7	99.5	99.8
Cancer screening rate	Stomach cancer screening	Non-consolidated	％	97.2	97.3	97.7	95.3	96.5
	Lung cancer screening	Non-consolidated	％	99.3	99.7	99.9	99.9	100.0
	Colorectal cancer screening	Non-consolidated	％	93.9	93.6	95.8	94.7	93.2
	Breast cancer screening	Non-consolidated	％	90	88.3	86.7	89.3	92.5
	Cervical cancer	Non-consolidated	％	43.4	42.3	47.3	46.6	52.3
Smoking rate		Non-consolidated		-	-	18.2	17.0	15.5
Difference between health age and actual age		Non-consolidated	Years old	-	-	-1.5	-1.4	-1.8

Mental health measures and health promotion
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Stress checks rate		Non-consolidated	％	95.1	99.4	99.8	99.5	98.7
Number of participants in walking campaign	Employees	Non-consolidated	Persons	1,088	1,169	1,450	1,417	1,582
	Family	Non-consolidated	Persons	472	771	987	985	1,027
	Temporary staff, etc.	Non-consolidated	Persons	99	90	124	89	117
Walking campaign all employee participation rate		Non-consolidated	％	34	35	44	42	47

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

GHG emissionsThe scope of environmental data is non-consolidated basis.
Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.
Item			Scope	Unit	FY2017	FY2018	FY2019	FY2020	★FY2021
GHG emissions (Market-basis)			Production and research sites	kt-CO₂	27.2	26.1	25.2	24.1	21.8
			Headquarters and other Sites in Japan (including tenant locations)	kt-CO₂	2.6	2.4	2.1	2.0	1.7
			Total	kt-CO₂	29.8	28.5	27.3	26.1	23.6
GHG emissions scope breakdown (Market-basis)	Scope 1 (Breakdown by GHG type)	Energy-derived	All operation sites	kt-CO₂	8.5	9.0	9.7	10.0	9.8
		Non-energy-derived (HFCs, HCFCs)			0.2	0.5	0.4	0.1	0.03
		Total			8.7	9.5	10.1	10.1	9.8
	Scope 2		All operation sites	kt-CO₂	21.1	19.1	17.1	15.9	13.7
Amount of CO₂ offset due to voluntary credit(Carbon-neutral city gas purchased)			Joto Pharmaceutical Product Development Center, Tsukuba Research Institute	kt-CO₂	-	-	-	-	0.6
GHG emissions after offset			All operation sites	kt-CO₂	-	-	-	-	23.0

Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
GHG emissions are calculated using the following formula.
GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
The amount of green electric power certified under the Green Energy Certificate and , the amount of renewable energy certified under the J-Credit Scheme and the Non-Fossil Fuel Certificate quota are deducted

GHG emissions in the value chain (Scope3)
Category		Calculation method	Notes	Scope	Unit	FY2017	FY2018	FY2019	FY2020	★FY2021
Cat1	Purchased goods and services	GHG emissions (scope 1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers.	·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included. ·Covers production and research sites ·Figures for FY2021 are not calculated because our major suppliers had not published their CSR reports at the time of calculation.	All operation sites	kt-CO₂	8.5	8.1	11.5	12.7	-
Cat2	Capital goods	Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor	Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities.		kt-CO₂	52.6	60.4	26.9	25.8	26.4
Cat3	Fuel- and energy-related activities not included in scope 1 or scope 2	Amount of non-renewable electricity purchased, multiplied by emission factor	-		kt-CO₂	1.5	1.5	2.8	2.7	2.4
Cat4	Upstream transportation and distribution	Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor	-		kt-CO₂	0.1	0.1	0.1	0.1	0.1
Cat5	Waste generated in operations	Weight of each type of industrial waste generated, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
Cat6	Business travel	Business travel costs, multiplied by emission factor	Covers travels by airplane or Shinkansen bullet train		kt-CO₂	2.5	2.3	4.0	0.4	0.5
Cat7	Employee commuting	Commuting costs, multiplied by emission factor	The commuting costs includes the amount for commuting by car from 2021		kt-CO₂	0.4	0.4	0.5	0.4	0.7
Cat8	Upstream leased assets	Fuel consumption used in leased vehicles, multiplied by emission factor	-		kt-CO₂	3.5	3.3	2.9	2.0	2.1
Cat9	Downstream transportation and distribution	GHG emissions stated in CSR reports on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers	·Transportation and　distribution are important business activities to control distribution of and to ensure stable supply of drugs. · Figures for FY2021 are not calculated because our major pharmaceutical wholesalers had not published their CSR reports at the time of calculation.		kt-CO₂	5.3	5.3	4.9	5.0	-
Cat10	Processing of sold products	-	We make only finished products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat11	Use of sold products	-	No energy is consumed during the use of ONO products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat12	End-of-life treatment of sold products	Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor	-		kt-CO₂	0.1	0.2	0.2	0.2	0.1
Cat13	Downstream leased assets	Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
Cat14	Franchises	-	ONO does not operate franchises		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat15	Investments	-	There is no investment involving large amounts of greenhouse gas emissions.		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Total					kt-CO₂	75.1	82.2	54.4	49.8	-

Categories 1 and 9 of scope 3 and their total for FY2021 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2017, Ver. 2.4; FY2018, Ver. 2.6; FY2019, Ver. 3.0; FY2020, Ver. 3.1; FY2021, Ver. 3.2)," published by the Ministry of the Environment, Government of Japan.

Energy consumption
Item			Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Energy consumption			Production and research sites	MWh	83,906.2	88,423.4	96,369.2	98,025.2	★94,433.7
			Headquarters and other Japan offices/sites (including tenant locations)	MWh	5,256.9	5,340.4	5,236.4	5,179.1	★5,004.3
			Total	MWh	89,163.1	93,763.8	101,605.6	103,204.3	★99,438.0
Share of renewable energy in total electricity consumption	Electricity consumption	Private power generation (renewable) (solar power generation)	All operation sites	MWh	55.3	65.0	63.0	63.3	61.9
		Purchased electricity (renewable) (Non-fossil fuel)		MWh	-	-	1,278.0	1,954.7	2,040.0
		Private power generation (non-renewable)		MWh	7,927.0	8,856.2	8,185.3	8,566.3	8,283.7
		Purchased electricity (non-renewable)		MWh	41,820.1	43,734.4	46,351.7	45,232.2	42,833.5
		Total (total electricity consumption)		MWh	49,802.4	52,655.5	55,878.0	55,816.5	53,219.2
	Amount of credits purchased	Solar power generation		MWh	-	-	2,427.0	4,946.6	3,937.9
	Amount of credits purchased	Biomass power generation		MWh	-	2,900.0	2,460.9	386.2	3,000.0
	Renewable energy usage^*5			MWh	55.3	2,965.0	6,228.9	7,350.7	★9,039.9
	Renewable energy usage rate (renewable energy usage / total electricity consumption)			％	0.1	5.6	11.1	13.2	★17.0

Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased

Water intake and wastewater volume by site (unit: 1,000 m³)
Site name	River in the area	Wastewater drainage destination	FY2017		FY2018		FY2019		FY2020		★FY2021
Site name	River in the area	Wastewater drainage destination	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume
Fujiyama Plant	Fuji River	River	205.6	148.6	240.2	178.4	185.0	145.1	157.8	125.0	138.7	110.2
Joto Pharmaceutical Product Development Center	Yodo River	Sewer	5.5	5.5	6.0	6.0	5.1	5.1	4.6	4.6	3.9	3.9
Yamaguchi Plant	Fushino River	River	-	-	8.2	8.2	18.1	18.1	18.6	17.7	21.6	20.0
Minase Research Institute	Yodo River	Sewer	51.3	51.3	41.2	41.2	39.1	39.1	33.7	33.7	31.5	31.5
Fukui Research Institute	Kuzuryu River	Sewer	38.7	5.2	31.3	5.0	27.3	5.7	13.7	2.6	6.6	1.9
Tsukuba Research Institute	Lake Kasumigaura	Sewer	8.1	8.1	6.0	6.0	7.1	7.1	7.2	7.2	7.0	7.0
Head Office and other sites in Japan (including tenant locations)	Rivers/lake in the areas where major business sites are located^*6	Sewer	15.9	15.9	15.1	15.1	15.0	15.0	10.0	10.0	10.0	10.0
Total			325.1	234.6	348.0	259.9	296.7	235.2	245.6	200.8	219.4	184.5

Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
Basins of major offices: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River

Activities to reduce water consumption (rate of recycled water)
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Percentage of reused water	Production and research sites	%	5.9	4.8	5.5	2.0	1.6

Waste Management, and Recycling Containers and Product Packaging
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Industrial waste	Waste generated	Production and research sites, etc.	t	719.1	446.4	430.8	502.7	★479.1
	Special management industrial waste (hazardous waste)^*7	Production and research sites, etc.	t	137.0	145.6	161.9	171.2	★170.3
	final landfill disposal	Production and research sites, etc.	t	7.4	0.4	0.2	1.1	★0.2
	final landfill disposal rate	Production and research sites, etc.	%	1.0	0.1	0.1	0.2	★0.04
final landfill disposal (Non-industrial waste is included)		Production and research sites	t	18.0	9.4	6.7	5.9	5.3
Container and packaging usage	Plastic	Production	t	164.7	171.7	162.8	161.5	147.0
	Paper	Production	t	192.0	202.7	200.9	198.1	175.6
	Glass (colorless)	Production	t	0.0	0.0	0.0	0.0	0.0
	Glass (brown)	Production	t	0.3	0.3	0.3	0.2	0.2
Obligatory recycling amount	Plastic	Production	t	34.7	35.5	31.2	35.1	36.6
	Paper	Production	t	1.6	1.6	1.5	1.4	1.3
	Glass (colorless)	Production	t	0.0	0.0	0.0	0.0	0.0
	Glass (brown)	Production	t	0.0	0.0	0.0	0.0	0.0
Commissioning fee paid for recycling		Production	1,000 yen	1,723.0	1,650.0	1,546.0	1,814.0	1,958.0

Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute /Logistics Center (added from FY2021)
The final industrial landfill disposal volume of industrial waste in FY2017 was calculated with inclusion of the amount of waste (5.8 tons) from the renovation of the Joto Pharmaceutical Product Development Center.
Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.

Prevention of Air Pollution and Water Pollution
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Emissions into the air	SOx	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	NOx	Production and research sites	t	7.8	8.4	8.1	8.1	8.3
	Particulate matter	Production and research sites	t	0.3	0.3	0.3	0.3	0.3
	PRTR substance	Production and research sites	t	0.2	0.2	0.1	0.4	0.3
Emissions into water	Wastewater	Production and research sites	1,000m³	218.7	244.8	220.2	190.8	★174.5
	BOD	Production and research sites	t	2.2	1.3	1.3	1.2	1.3
	PRTR substance	Production and research sites	t	0.0	0.0	0.0	0.0	0.0

Management of Chemicals (PRTR substances)
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Amount handled by the notified facilities	Acetonitrile	Production and research sites	t	9.0	7.2	8.5	10.4	9.3
	Normal-hexane	Production and research sites	t	3.0	2.8	3.0	2.6	2.3
	Total	Production and research sites	t	12.0	10.0	11.5	13.0	11.6
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-
Notified release (into the air)	Acetonitrile	Production and research sites	t	0.4	0.2	0.1	0.3	0.3
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.4	0.2	0.1	0.3	0.3
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-
Notified release (into public waters)	Acetonitrile	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-
Notified transfer (contained in waste)	Acetonitrile	Production and research sites	t	8.8	6.9	8.4	10.1	8.9
	Normal-hexane	Production and research sites	t	3.0	2.8	3.0	2.6	2.3
	Total	Production and research sites	t	11.8	9.8	11.3	12.7	11.3
	Dioxins	Production and research sites	mg-TEQ	0.0	-	-	-	-
Notified transfer (Into public sewage)	Acetonitrile	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-
Notified release and transfer (total)	Acetonitrile	Production and research sites	t	9.0	7.2	8.5	10.4	9.3
	Normal-hexane	Production and research sites	t	3.0	2.8	3.0	2.6	2.3
	Total	Production and research sites	t	12.0	10.0	11.5	13.0	11.6
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-

Management of Chemicals (PCB)
Item		Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Joto Pharmaceutical Product Development Center	In use or stored	Production and research sites	Stand	552	552	0	0	0
Minase Research Institute	In use or stored	Production and research sites	Stand	0	0	0	0	2

In FY2019, the Joto Pharmaceutical Product Development Center brought in 552 units of equipment to the Japan Environmental Storage and Safety Corporation, a processing facility, and disposed of them appropriately. One condenser was found at the Joto Pharmaceutical Product Development Center in FY2020, but it was properly disposed of in FY2020. The Minase Research Institute found that two transformers in use fell within the scope of the “Act on Special Measures concerning Promotion of Proper Treatment of PCB Wastes” in 2021, and submitted a report on the storage and disposal of waste of polychlorinated biphenyls to the Osaka municipal government.

Environmental Management
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Status of acquisition of ISO 14001 certification for sites	Production	site	100%	100%	100%	100%	100%

Scope of ISO 14001 certification at production sites.

Environmental Violations
Item	Scope	Unit
Number of breaches of legal obligation/regulatory violations	All operation sites	Cases
Amount of breach-/violation-related fines	All operation sites	Million yen
Environmental liabilities as of fiscal year-end	All operation sites	Million yen

Breach/violation cases with fines of USD 10,000 or more
The above includes violations related to air and soil pollution, noise, vibration, and water quality.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item	Scope	Unit	FY2017	FY2018	FY2019	FY2020	FY2021
Osamu Hayaishi Memorial Award	-	Persons	1	1	1	1	1
Recipients of theresearch grant	-	Persons	12	12	12	12	12
Recipients of theresearch scholarship grant（40 years old and below）	-	Persons	16	16	16	16	16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad	-	Persons	8	8	8	8	8

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system